DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Sargramostim is an investigational drug.
There have been 261 clinical trials for Sargramostim. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2011.
The most common disease conditions in clinical trials are Leukemia, Lymphoma, and Multiple Myeloma. The leading clinical trial sponsors are National Cancer Institute (NCI), M.D. Anderson Cancer Center, and Bayer.
There are one hundred and four US patents protecting this investigational drug and one international patent.
Recent Clinical Trials for Sargramostim
|pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer||Madison Vaccines, Inc||Phase 2|
|pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer||Merck Sharp & Dohme Corp.||Phase 2|
|pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer||Prostate Cancer Foundation||Phase 2|
Top disease conditions for Sargramostim
Top clinical trial sponsors for Sargramostim
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Sargramostim||See Pricing||Trilayer coated pharmaceutical packaging||SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL)||See Pricing|
|Sargramostim||See Pricing||TLR-agonist-conjugated antibody recruiting molecules (TLR-ARMs)||YALE UNIVERSITY (New Haven, CT)||See Pricing|
|Sargramostim||See Pricing||Compositions comprising serum albumin and p53 peptides fusion proteins||University of the Sciences of Philadelphia (Philadelphia, PA)||See Pricing|
|Sargramostim||See Pricing||Compositions comprising granulocyte-macrophage colony-stimulating factor for the treatment of inflammatory bowel disease||Reponex Pharmaceuticals A/S (Horsholm, DK)||See Pricing|
|Sargramostim||See Pricing||Synthetic antibody mimetic compounds (SYAMS) targeting cancer, especially prostate cancer||YALE UNIVERSITY (New Haven, CT)||See Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|